Cardiac emergencies: Infective endocarditis, pericarditis, and myocarditis

Medical Clinics of North America

Volumn 96, Issue 6, 2012, Pages 1149-1169

  Htwe, Tin Han ^a   Khardori, Nancy Misri ^b  

^a Sentara Medical Group   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Congestive heart failure; Fever; Infective endocarditis; Leukocytosis; Myocarditis; Pericarditis

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLAVULANIC ACID; COLCHICINE; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERFERON; LINEZOLID; NAFCILLIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXACILLIN; PENICILLIN G; RIFAMPICIN; STREPTOMYCIN; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART TAMPONADE; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; LEUKOCYTOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGICAL EXAMINATION; MYOCARDITIS; NONHUMAN; PERICARDITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTHETIC VALVE ENDOCARDITIS; PSEUDOMONAS INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION;

ARRHYTHMIAS, CARDIAC; CORONARY DISEASE; EMERGENCY SERVICE, HOSPITAL; ENDOCARDITIS, BACTERIAL; EVIDENCE-BASED MEDICINE; HEART DISEASES; HEART VALVE DISEASES; HUMANS; PROGNOSIS; PULMONARY EMBOLISM; QUALITY ASSURANCE, HEALTH CARE;

EID: 84868159805     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.09.003     Document Type: Review

References (79)

1. Fowler V., Scheld W., Bayer A. Endocarditis and intravascular infections. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, 1067-1112. Elsevier Churchill Livingstone, Philadelphia. 7th edition. G.L. Mandell, J. Bennett, R. Dolin (Eds.).
2. Murdoch D.R., Corey G.R., Hoen B., et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective cohort study. Arch Intern Med 2009, 169(5):463-473.
3. Duval X., Delahaye F., Alla F., et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol 2012, 59(22):1968-1976.
4. Wang A. The changing epidemiology of infective endocarditis: the paradox of prophylaxis in the current and future eras. J Am Coll Cardiol 2012, 59(22):1977-1978.
5. Dzupova O., Machala L., Baloun R., et al. Incidence, predisposing factors, and aetiology of infective endocarditis in the Czech Republic. Scand J Infect Dis 2012, 44(4):250-255.
6. Thuny F., Hubert S., Tribouilloy C., et al. Sudden death in patients with infective endocarditis: findings from a large cohort study. Int J Cardiol 2012, [Epub ahead of print].
7. Sandre R.M., Shafran S.D. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996, 22(2):276-286.
8. Sousa C., Botelho C., Rodrigues D., et al. Infective endocarditis in intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis 2012, [Epub ahead of print].
9. Sohail M., Uslan D., Khan A., et al. Microbiology and pathogenesis of cardiovascular implantable electronic device infections. Mayo Clin Proc 2008, 83(Issue 1):46-53.
10. Nagpal A., Baddour L.M., Sohail M.R. Microbiology and pathogenesis of cardiovascular implantable electronic device infections. Circ Arrhythm Electrophysiol 2012, 5(2):433-441.
11. Gandhi T., Crawford T., Riddell J. Cardiovascular implantable electronic device associated infections. Infect Dis Clin North Am 2012, 26(1):57-76.
12. Fernández Guerrero M.L., González López J.J., Goyenechea A., et al. Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. Medicine (Baltimore) 2009, 88(1):1-22.
13. Cabell C.H., Jollis J.G., Peterson G.E., et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002, 162:90-94.
14. Fowler V.G., Miro J.M., Hoen B., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005, 293:3012-3021.
15. Lalani T., Kanafani Z.A., Chu V.H., et al. Prosthetic valve endocarditis due to coagulase-negative staphylococci: findings from the International Collaboration on Endocarditis Merged Database. Eur J Clin Microbiol Infect Dis 2006, 25(6):365-368.
16. Hoovels L., Munter P., Colaert J., et al. Three cases of destructive native valve endocarditis caused by Staphylococcus lugdunensis. Eur J Clin Microbiol Infect Dis 2005, 24:149-152.
17. Morpeth S., Murdoch D., Cabell C.H., et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med 2007, 147:829-835.
18. Nasim A., Baqi S., Akhtar S.F. Pseudomonas aeruginosa endocarditis in renal transplant recipients. Transpl Infect Dis 2012, 14(2):180-183. 10.1111/j.1399-3062.2011.00667.x.
19. Hassan K.S., Al-Riyami D. Infective endocarditis of the aortic valve caused by pseudomonas aeruginosa and treated medically in a patient on haemodialysis. Sultan Qaboos Univ Med J 2012, 12(1):120-123.
20. Baddley J.W., Benjamin D.K., Patel M., et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008, 27(7):519-529.
21. Habib G., Hoen B., Tornos P., et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. Eur Heart J 2009, 30(19):2369-2413.
22. Khan F., Khakoo R., Failinger C. Managing embolic myocardial infarction in infective endocarditis: current options. J Infect 2005, 51(3):e101-e105.
23. Voss F., Bludau H.B., Haller C. Mitral valve endocarditis: an uncommon cause of myocardial infarction. Z Kardiol 2003, 92(8):686-688.
24. Koike S., Takayama S., Furihata A., et al. Infective endocarditis causing acute myocardial infarction by compression of the proximal left coronary artery due to a mycotic aneurysm of the sinus of Valsalva. Jpn Circ J 1991, 55(12):1228-1232.
25. Ural E., Bldirici U., Kahraman G., et al. Coronary embolism complicating aortic valve endocarditis: treatment with successful coronary angioplasty. Int J Cardiol 2007, 119(3):377-379.
26. Anguera I., Quaglio G., Ferrer B., et al. Sudden death in Staphylococcus aureus-associated infective endocarditis due to perforation of a free-wall myocardial abscess. Scand J Infect Dis 2001, 33(8):622-625.
27. Anguera I., Miro J.M., Evangelista A., et al. Periannular complications in infective endocardities involving native aortic valves. Am J Cardiol 2006, 98(9):1254-1260.
28. Anguera I., Miro J.M., Cabell C.H., et al. Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the international collaboration on endocarditis merged database. Am J Cardiol 2005, 96(7):976-981.
29. Satoh T., Nishida N. Patent ductus arteriosus with infective endocarditis at age 92. Intern Med 2008, 47(4):263-268.
30. Branch J., Suganami Y., Kitagawa I., et al. A rare case of group a streptococcal endocarditis with absence of valvular vegetation. Intern Med 2010, 49(15):1657-1661.
31. Barg N.L., Kish M.A., Kauffman C.A., et al. Group a streptococcal bacteremia in intravenous drug abusers. Am J Med 1985, 78:569-574.
32. Winterbotham A., Riley S., Kavanaugh-McHugh A., et al. Endocarditis caused by group a beta-hemolytic streptococcus in an infant: case report and review. Clin Infect Dis 1999, 29:196-198.
33. Tyrrell G.J., Lovgren M., Kress B., et al. Varicella-associated invasive group a streptococcal disease in alberta, Canada-2000-2002. Clin Infect Dis 2005, 40:1055-1057.
34. Ramirez C.A., Naraqi S., McCulley D.J. Group a beta-hemolytic streptococcus endocarditis. Am Heart J 1984, 108:1383-1386.
35. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 2005, 111(23):e394-e434.
36. Fowler V.G., Li J., Corey G.R., et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997, 30(4):1072-1078.
37. De Castro S., Cartoni D., d'Amati G., et al. Diagnostic accuracy of transthoracic and multiplane transesophageal echocardiography for valvular perforation in acute infective endocarditis: correlation with anatomic findings. Clin Infect Dis 2000, 30(5):825-826.
38. Palraj B.R., Sohail M.R. Appropriate use of echocardiography in managing Staphylococcus aureus bacteremia. Expert Rev Anti Infect Ther 2012, 10(4):501-508.
39. Hill E.E., Herijgers P., Claus P., et al. Clinical and echocardiographic risk factors for embolism and mortality in infective endocarditis. Eur J Clin Microbiol Infect Dis 2008, 27(12):1159-1164.
40. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
41. Rehm S.J., Boucher H., Levine D., et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008, 62(6):1413-1421.
42. Moore C.L., Osaki-Kiyan P., Haque N.Z., et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012, 54(1):51-58.
43. Cosgrove S.E., Vigliani G.A., Fowler V.G., et al. Initial low-dose gentamicin for staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009, 48(6):713-721.
44. Tsuji B.T., Rybak M.J. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005, 49(7):2735-2745.
45. Bayer A.S., Hirano L., Yih J. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother 1988, 32:231-235.
46. Pefanis A., Giamarellou H., Karayiannakos P., et al. Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother 1993, 37:308-313.
47. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis. Clin Infect Dis 2009, 48(5):503-535.
48. Garzoni C., Nobre V.A., Garbino J. Candida parapsilosis endocarditis: a comparative review of the literature. Eur J Clin Microbiol Infect Dis 2007, 26:915-926.
49. Lye D., Hughes A., O'Brien D., et al. Candida glabrata prosthetic valve endocarditis, treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis 2005, 24:753-755.
50. Gelsomino S., Maessen J.G., van der Veen F., et al. Emergency surgery for native mitral valve endocarditis: the impact of septic and cardiogenic shock. Ann Thorac Surg 2012, 93(5):1469-1476.
51. Kang D.H., Kim Y.J., Kim S.H., et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 2012, 366(26):2466-2473.
52. Lange R.A., Hillis L.D. Clinical practice. Acute pericarditis. N Engl J Med 2004, 351(21):2195-2202.
53. Rahman A., Liu D. Pericarditis-clinical features and management. Aust Fam Physician 2011, 40(10):791-796.
54. Tingle L.E., Molina D., Calvert C.W. Acute pericarditis. Am Fam Physician 2007, 76(10):1509-1514.
55. Imazio M., Spodick D.H., Brucato A., et al. Controversial issues in the management of pericardial diseases. Circulation 2010, 121(7):916-928.
56. Parikh S.V., Memon N., Echols M., et al. Purulent pericarditis: report of 2 cases and review of the literature. Medicine (Baltimore) 2009, 88(1):52-65.
57. Katz L.H., Pitlik S., Porat E., et al. Pericarditis as a presenting sign of infective endocarditis: two case reports and review of the literature. Scand J Infect Dis 2008, 40(10):785-791.
58. Tatli E., Buyuklu M., Altun A. An unusual complication of pneumococcal pneumonia: acute tamponade due to purulent pericarditis. Int J Cardiol 2007, 119(1):e1-e3.
59. Vindas-Cordero J.P., Sands M., Sanchez W. Austrian's triad complicated by suppurative pericarditis and cardiac tamponade: a case report and review of the literature. Int J Infect Dis 2009, 13(1):e23-e25.
60. Chaudhry R., Verma N., Bahadur T., et al. Clostridium sordellii as a cause of constrictive pericarditis with pyopericardium and tamponade. J Clin Microbiol 2011, 49(10):3700-3702.
61. Nei T., Hyodo H., Sonobe K., et al. First report of infectious pericarditis due to Bordetella holmesii in an adult patient with malignant lymphoma. J Clin Microbiol 2012, 50(5):1815-1817.
62. Delvallée M., Ettahar N., Loïez C., et al. An unusual case of fatal pericarditis due to Listeria monocytogenes. Jpn J Infect Dis 2012, 65(4):312-314.
63. Ntsekhe M., Mayosi B.M. Tuberculous pericarditis with and without HIV. Heart Fail Rev 2012, [Epub ahead of print].
64. Cooper L. Myocarditis. N Engl J Med 2009, 360:1526-1538.
65. Knowlton K., Savoia M., Oxman M. Myocarditis and pericarditis. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, 1153-1171. Elsevier Churchill Livingstone, Philadelphia. 7th edition. vol. 1. G.L. Mandell, J. Bennett, R. Dolin (Eds.).
66. Mahrholdt H., Wagner A., Deluigi C.C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006, 114:1581-1590.
67. Hufnagel G., Pankuweit S., Richter A., et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz 2000, 25:279-285.
68. Babamahmoodi F., Davoodi A., Ghasemian R., et al. Report of two rare complications of pandemic influenza a (H1N1). J Infect Dev Ctries 2012, 6(2):204-207.
69. Sharma U., Tak T. A report of 2 cases of myopericarditis after Vaccinia virus (smallpox) immunization. WMJ 2011, 110(No 6):291-294.
70. Lee W.S., Lee K.J., Kwon J.E., et al. Acute viral myopericarditis presenting as a transient effusive-constrictive pericarditis caused by coinfection with coxsackieviruses A4 and B3. Korean J Intern Med 2012, 27(2):216-220.
71. LeLeiko R.M., Bower D.J., Larsen C.P. MRSA-associated bacterial myocarditis causing ruptured ventricle and tamponade. Cardiology 2008, 111(3):188-190.
72. Raev D. Acute staphylococcal myocarditis masquerading as an acute myocardial infarction. Int J Cardiol 1997, 60(1):95-98.
73. Boruah P., Shetty S., Kumar S.S. Acute streptococcal myocarditis presenting as acute ST-elevation myocardial infarction. J Invasive Cardiol 2010, 22(10):E189-E191.
74. Horowitz H.W., Belkin R.N. Acute myopericarditis resulting from Lyme disease. Am Heart J 1995, 130(1):176-178.
75. Imazio M., Cecchi E., Demichelis B., et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008, 94:498-501.
76. Costantini M., Oreto G., Albanese A., et al. Presumptive myocarditis with ST-Elevation myocardial infarction presentation in young males as a new syndrome. Clinical significance and long term follow up. Cardiovasc Ultrasound 2011, 9:1.
77. Deluigi C., Ong P., Hill S., et al. ECG findings in comparison to cardiovascular MR imaging in viral myocarditis. Int J Cardiol 2011, 10.1016/j.ijcard.2011.07.090.
78. Parrillo J.E., Cunnion R.E., Epstein S.E., et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989, 321(16):1061-1068.
79. Mason J.W., O'Connell J.B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N Engl J Med 1995, 333(5):269-275.